ArticleCardiovascular intervention and therapeutics2026
Association of pre-procedural activities of daily living status with all-cause mortality after femoropopliteal endovascular therapy.
Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-procedural functional status may influence prognosis after peripheral endovascular intervention, yet the independent prognostic value of activities of daily living (ADL) status for outcomes after femoropopliteal endovascular therapy (FP-EVT) remains unclear. We retrospectively analyzed 418 consecutive patients undergoing their first FP-EVT at a single center. Pre-procedural ADL was classified as independent (n = 207), ambulatory with assistance (n = 87), wheelchair-bound (n = 95), or bedridden (n = 29). The primary endpoint was all-cause mortality; cause-specific mortality (Fine-Gray models) was secondary, and major adverse cardiovascular events (MACE) and major adverse limb events (MALE) were exploratory. During a median follow-up of 18.1 months, 125 deaths (29.9%) occurred, increasing stepwise across ADL groups (12.6%, 37.9%, 49.5%, 65.5%; 3-year mortality-free survival 85.2%, 62.2%, 50.3%, 24.6%; log-rank P < 0.001). Each one-step ADL decline was independently associated with mortality (hazard ratio [HR] 1.49; 95% confidence interval [CI] 1.17-1.89; P = 0.001). In cause-specific analyses, ADL was most strongly associated with infection-related death (subdistribution HR 1.97; 95% CI 1.50-2.59; P < 0.001). The mortality association was consistent across claudication (HR 1.47; 95% CI 0.98-2.20) and chronic limb-threatening ischemia (CLTI; HR 1.48; 95% CI 1.15-1.92), with no significant interaction (P = 0.699). ADL was not independently associated with MACE or MALE. Non-cardiovascular causes accounted for 76.8% of deaths, with infection the leading cause (39.2%). Pre-procedural ADL status was independently associated with all-cause mortality after FP-EVT, most strongly with infection-related death, and consistently across clinical presentations. Routine ADL assessment may enhance pre-procedural risk stratification.
Indexed as
Identifiers
42608617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.